30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Coeptis Therapeutics Holdings Inc (COEP)

Track

Over the last 90 days, insider trading activity at Coeptis Therapeutics Holdings Inc. shows one transaction with a total value of $64,100. This was a sale by Director Daniel Alexander Yerace. The company's stock has seen a 36.7% increase in the last 90 days. The last earnings report in March 2023 missed expectations significantly.
Stock chart
Ticker: COEP Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Yerace Daniel Alexander
Director
1 sale — total 64,100 USD
Proposed sale 16 Apr 2026
Value US$29,571.11 | Price 408.89 | Shares 96,604
Proposed sale 15 Dec 2025
Value US$4,835,962.56 | Price 487.82 | Shares 61,741
Proposed sale 2 Sep 2025
Value US$64,800.00 | Price 12.96 | Shares 5,000
Buy 12 Jan 2024
Value US$1,044.00 | Price 0.58 | Shares 1,800
Buy 12 Jan 2024
Value US$260.96 | Price 0.56 | Shares 466
Buy 10 Jan 2024
Value US$3,350.00 | Price 0.67 | Shares 5,000
Buy 8 Jan 2024
Value US$9,242.64 | Price 0.66 | Shares 14,004
Buy 8 Jan 2024
Value US$4,020.00 | Price 0.67 | Shares 6,000
Buy 5 Jan 2024
Value US$7,486.50 | Price 0.69 | Shares 10,850
Buy 5 Jan 2024
Value US$3,484.50 | Price 0.69 | Shares 5,050
Buy 5 Jan 2024
Value US$5,390.00 | Price 0.77 | Shares 7,000
Buy 5 Jan 2024
Value US$8,004.00 | Price 0.69 | Shares 11,600
Buy 29 Aug 2023
Value US$4,046.06 | Price 1.01 | Shares 4,006
Buy 25 Aug 2023
Value US$26,060.58 | Price 0.91 | Shares 28,638
Buy 23 Aug 2023
Value US$2,418.56 | Price 0.94 | Shares 2,582
Buy 23 Aug 2023
Value US$8,460.00 | Price 0.94 | Shares 9,000
Sale 4 May 2022
Value US$862,433.55 | Price 10.11 | Shares 85,305
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-16 2026-04-16 PrS Proposed sale
0.5
Yerace Daniel Alexander

Director

Non-Executive Director
96,604
408.89
US$29,571 		96,604 408.89 US$29,571
2025-12-15 2025-12-15 PrS Proposed sale
0.5
Yerace Daniel Alexander

Director

Non-Executive Director
61,741
487.82
US$4,835,963 		61,741 487.82 US$4,835,963
2025-09-02 2025-09-02 PrS Proposed sale
0.5
Yerace Daniel Alexander

Director

Non-Executive Director
52,358
103.90
US$1,381,568 		52,358 103.90 US$1,381,568
2024-01-16 2024-01-12 B Purchase
0.6
DeSilva Tara
Non-Executive Director
1,800 +5.9%
0.58
US$1,044 		1,800 +5.9% 0.58 US$1,044
2024-01-16 2024-01-12 B Purchase
0.6
DeSilva Tara
Non-Executive Director
466 +1.6%
0.56
US$261 		466 +1.6% 0.56 US$261
2024-01-17 2024-01-10 B Purchase
0.5
Cogley Brian

Chief Financial Officer

Officer
5,000 +20.0%
0.67
US$3,350 		5,000 +20.0% 0.67 US$3,350
2024-01-09 2024-01-08 B Purchase
0.8
Mehalick David

CEO and President

Executive Director Large shareholder
14,004 +0.5%
0.66
US$9,243 		14,004 +0.5% 0.66 US$9,243
2024-01-09 2024-01-08 B Purchase
0.8
Mehalick David

CEO and President

Executive Director Large shareholder
6,000 +0.2%
0.67
US$4,020 		6,000 +0.2% 0.67 US$4,020
2024-01-09 2024-01-05 B Purchase
0.5
Yerace Daniel Alexander

VP of Operations

Executive Director
10,850 +1.0%
0.69
US$7,486 		10,850 +1.0% 0.69 US$7,486
2024-01-09 2024-01-05 B Purchase
0.8
Mehalick David

CEO and President

Executive Director Large shareholder
5,050 +0.2%
0.69
US$3,484 		5,050 +0.2% 0.69 US$3,484
2024-01-09 2024-01-05 B Purchase
Cochran Christopher P.
Non-Executive Director
7,000 +23.3%
0.77
US$5,390 		7,000 +23.3% 0.77 US$5,390
2024-01-09 2024-01-05 B Purchase
2.4
Salkind Gene
Non-Executive Director
11,600 +4.3%
0.69
US$8,004 		11,600 +4.3% 0.69 US$8,004
2023-08-30 2023-08-29 B Purchase
2.4
Salkind Gene
Non-Executive Director
4,006 +10015.0%
1.01
US$4,046 		4,006 +10015.0% 1.01 US$4,046
2023-08-30 2023-08-25 B Purchase
2.4
Salkind Gene
Non-Executive Director
28,638 +inf%
0.91
US$26,061 		28,638 +inf% 0.91 US$26,061
2023-08-31 2023-08-23 B Purchase
1.8
Calise Chris
Non-Executive Director
2,582 +0.2%
0.94
US$2,419 		2,582 +0.2% 0.94 US$2,419
2023-08-31 2023-08-23 B Purchase
1.8
Calise Chris
Non-Executive Director
9,000 +0.6%
0.94
US$8,460 		9,000 +0.6% 0.94 US$8,460
2022-05-06 2022-05-04 S Sale
2.9
Harraden Circle Investments, LLC
Large shareholder
85,305 -16.6%
10.11
US$862,434 		85,305 -16.6% 10.11 US$862,434
Explore more

More insider trading research around Coeptis Therapeutics Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America